NasdaqGM:KIDS

Stock Analysis Report

Executive Summary

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally.

Snowflake

Fundamentals

Reasonable growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has OrthoPediatrics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

4.4%

NasdaqGM:KIDS

0.5%

US Medical Equipment

-0.02%

US Market


1 Year Return

23.4%

NasdaqGM:KIDS

9.9%

US Medical Equipment

1.6%

US Market

KIDS outperformed the Medical Equipment industry which returned 9.7% over the past year.

KIDS outperformed the Market in United States of America which returned 1.9% over the past year.


Share holder returns

KIDSIndustryMarket
7 Day4.4%0.5%-0.02%
30 Day20.1%0.09%2.7%
90 Day-4.8%2.0%1.4%
1 Year23.4%23.4%10.8%9.9%3.8%1.6%
3 Yearn/a69.0%63.9%45.2%35.8%
5 Yearn/a136.2%109.3%61.8%44.1%

Price Volatility Vs. Market

How volatile is OrthoPediatrics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is OrthoPediatrics undervalued based on future cash flows and its price relative to the stock market?

6.54x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for OrthoPediatrics to establish if it is available at moderate discount.

Unable to calculate intrinsic value for OrthoPediatrics to establish if it is available at substantial discount.


Price Based on Earnings

OrthoPediatrics is loss making, we can't compare its value to the US Medical Equipment industry average.

OrthoPediatrics is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for OrthoPediatrics, we can't assess if its growth is good value.


Price Based on Value of Assets

OrthoPediatrics is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is OrthoPediatrics expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

81.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

OrthoPediatrics's revenue is expected to grow by 19.9% yearly, however this is not considered high growth (20% yearly).

OrthoPediatrics's earnings are expected to grow significantly at over 20% yearly.

OrthoPediatrics's revenue growth is expected to exceed the United States of America market average.

OrthoPediatrics's earnings growth is expected to exceed the United States of America market average.

OrthoPediatrics's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if OrthoPediatrics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has OrthoPediatrics performed over the past 5 years?

-6.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

OrthoPediatrics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare OrthoPediatrics's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare OrthoPediatrics's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if OrthoPediatrics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if OrthoPediatrics has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if OrthoPediatrics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is OrthoPediatrics's financial position?


Financial Position Analysis

OrthoPediatrics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

OrthoPediatrics's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

OrthoPediatrics's level of debt (58.2%) compared to net worth is high (greater than 40%).

Unable to establish if OrthoPediatrics's debt level has increased without past 5-year debt data.


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 2.1x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

OrthoPediatrics has less than a year of cash runway based on current free cash flow.

OrthoPediatrics has sufficient cash runway for 1.7 years if free cash flow continues to grow at historical rates of 51.9% each year.


Next Steps

Dividend

What is OrthoPediatrics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate OrthoPediatrics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate OrthoPediatrics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as OrthoPediatrics has not reported any payouts.

Unable to verify if OrthoPediatrics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as OrthoPediatrics has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of OrthoPediatrics's salary, the management and board of directors tenure and is there insider trading?

8.7yrs

Average management tenure


CEO

Mark Throdahl (68yo)

8.7yrs

Tenure

US$716,803

Compensation

Mr. Mark C. Throdahl has been the President and Chief Executive Officer of OrthoPediatrics Corp. since January 2011. Mr. Throdahl has more than 30 years of leadership experience in the medical products an ...


CEO Compensation Analysis

Mark's remuneration is lower than average for companies of similar size in United States of America.

Mark's compensation has increased whilst company is loss making.


Management Age and Tenure

8.7yrs

Average Tenure

50yo

Average Age

The average tenure for the OrthoPediatrics management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

8.2yrs

Average Tenure

63yo

Average Age

The tenure for the OrthoPediatrics board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Mark Throdahl (68yo)

    President

    • Tenure: 8.7yrs
    • Compensation: US$716.80k
  • Fred Hite (51yo)

    CFO & Director

    • Tenure: 4.1yrs
    • Compensation: US$648.92k
  • David Bailey (40yo)

    Executive Vice President

    • Tenure: 10.7yrs
    • Compensation: US$589.65k
  • Peter Armstrong (72yo)

    Chief Medical Officer & Chair of Surgeon Advisory Board

    • Tenure: 0yrs
  • Greg Odle (49yo)

    Executive Vice President of Commercialization

    • Tenure: 0yrs
    • Compensation: US$730.85k
  • Daniel Gerritzen (49yo)

    VP of Legal & Human Resources

    • Tenure: 10.7yrs
    • Compensation: US$441.62k

Board Members

  • Terry Schlotterback (63yo)

    Chairman

    • Tenure: 6yrs
    • Compensation: US$66.83k
  • Mark Throdahl (68yo)

    President

    • Tenure: 8.7yrs
    • Compensation: US$716.80k
  • Fred Hite (51yo)

    CFO & Director

    • Tenure: 4.1yrs
    • Compensation: US$648.92k
  • Bernie Berry (66yo)

    Director

    • Tenure: 10.7yrs
    • Compensation: US$60.83k
  • Kevin Unger (47yo)

    Director

    • Tenure: 8.7yrs
    • Compensation: US$57.83k
  • Peter Armstrong (72yo)

    Chief Medical Officer & Chair of Surgeon Advisory Board

    • Tenure: 0yrs
  • David Pelizzon (63yo)

    Director

    • Tenure: 8.7yrs
    • Compensation: US$60.83k
  • Bryan Hughes (42yo)

    Director

    • Tenure: 7.7yrs
    • Compensation: US$63.83k
  • Henry Chambers

    Member of Surgeon Advisory Board

    • Tenure: 0yrs
  • Marie Infante (69yo)

    Director

    • Tenure: 5.7yrs
    • Compensation: US$63.83k

Company Information

OrthoPediatrics Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: OrthoPediatrics Corp.
  • Ticker: KIDS
  • Exchange: NasdaqGM
  • Founded: 2007
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$576.071m
  • Shares outstanding: 14.94m
  • Website: https://www.orthopediatrics.com

Number of Employees


Location

  • OrthoPediatrics Corp.
  • 2850 Frontier Drive
  • Warsaw
  • Indiana
  • 46582
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
KIDSNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDOct 2017
2X7DB (Deutsche Boerse AG)YesCommon StockDEEUROct 2017

Biography

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States a ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/19 01:01
End of Day Share Price2019/09/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.